ArticleClinical and experimental immunology2010
Novel chimeric thyroid-stimulating hormone-receptor bioassay for thyroid-stimulating immunoglobulins.
Article in Clinical and experimental immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 74 citations in OpenAlex.
- A luminescent calcium biosensor enabling endpoint measurement of GPCR-mediated calcium signaling.Communications biology · 2026Article
- Graves' disease in ectopic thyroid tissue: a scoping review and a case study.European thyroid journal · 2025Article
- A case of severe neonatal hypercalcaemia secondary to neonatal thyrotoxicosis.Endocrinology, diabetes & metabolism case reports · 2025Article
- Analysis of non-cholesterol sterols and fatty acids in patients with graves' orbitopathy: insights into lipid metabolism in relation to the clinical phenotype of disease.Journal of endocrinological investigation · 2025Article
- Assessment of disease activity in Graves' orbitopathy.Frontiers in ophthalmology · 2025Review
- The phenotype of Graves' orbitopathy is associated with thyrotropin receptor antibody levels.Journal of endocrinological investigation · 2023Article
- Longitudinal association of thyroid-stimulating immunoglobulin levels with clinical characteristics in thyroid eye disease.BMJ open · 2022Observational
- The Prediction Model Using Thyroid-stimulating Immunoglobulin Bioassay For Relapse of Graves' Disease.Journal of the Endocrine Society · 2022Article
- Sensitivity of three thyrotropin receptor antibody assays in thyroid-associated orbitopathy.Journal of medical biochemistry · 2022Article
- Clinical value of functional thyrotropin receptor antibodies in Serbian patients with Graves' orbitopathy.Journal of endocrinological investigation · 2022Article
- Quality of life of patients with thyroid eye disease: 3-year follow-up in a multidisciplinary clinic in Israel.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2021Article
- Thyrotropin receptor antibodies and Graves' orbitopathy.Journal of endocrinological investigation · 2021Review
- The prognostic value of thyroid-stimulating immunoglobulin in the management of Graves' disease.Therapeutic advances in endocrinology and metabolism · 2021Article
- A Novel Long-Term Graves' Disease Animal Model Confirmed by Functional Thyrotropin Receptor Antibodies.European thyroid journal · 2020Article
- Management of Graves Thyroidal and Extrathyroidal Disease: An Update.The Journal of clinical endocrinology and metabolism · 2020Review
- Prospective Trial of Functional Thyrotropin Receptor Antibodies in Graves Disease.The Journal of clinical endocrinology and metabolism · 2020Article
- Comparison of a Novel Homogeneous Cyclic Amp Assay and a Luciferase Assay for Measuring Stimulating Thyrotropin-Receptor Autoantibodies.European thyroid journal · 2020Article
- Reply to Drs. Kiaei and Molinaro Regarding the Publication "Comparison of a Bridge Immunoassay with Two Bioassays for Thyrotropin Receptor Antibody Detection and Differentiation".Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2020Article
- Comparison of Five TSH-Receptor Antibody Assays in Graves' disease: results from an observational pilot study.BMC endocrine disorders · 2019Observational
- Thyrotropin Receptor Blocking Antibodies.Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid-stimulating immunoglobulins (TSI) are a functional biomarker of Graves' disease (GD). To develop a novel TSI bioassay, a cell line (MC4-CHO-Luc) was bio-engineered to constitutively express a chimeric TSH receptor (TSHR) and constructed with a cyclic adenosine monophosphate (cAMP)-dependent luciferase reporter gene that enables TSI quantification. Data presented as percentage of specimen-to-reference ratio (SRR%) were obtained from 271 patients with various autoimmune and thyroid diseases and 180 controls. Sensitivity of 96% and specificity of 99% for untreated GD were attained by receiver operating characteristic analysis, area under the curve 0·989, 95% confidence interval 0·969-0·999, P = 0·0001. Precision testing of manufactured reagents of high, medium, low and negative SRR% gave a percentage of coefficient-of-variation of 11·5%, 12·8%, 14·5% and 15·7%, respectively. There was no observed interference by haemoglobin, lipids and bilirubin and no non-specific stimulation by various hormones at and above physiological concentrations. TSI levels from GD patients without (SRR% 406 ± 134, mean ± standard deviation) or under anti-thyroid treatment (173 ± 147) were higher (P < 0·0001) compared with TSI levels of patients with Hashimoto's thyroiditis (51 ± 37), autoimmune diseases without GD (24 ± 10), thyroid nodules (30 ± 26) and controls (35 ± 18). The bioassay showed greater sensitivity when compared with anti-TSHR binding assays. In conclusion, the TSI-Mc4 bioassay measures the functional biomarker accurately in GD with a standardized protocol and could improve substantially the diagnosis of autoimmune diseases involving TSHR autoantibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.